Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells

The efficacy of osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has been evaluated in glioblastoma (GBM) through preclinical and clinical trials. However, the underlying mechanism of osimertinib-induced GBM cell death and the underlying resistance mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Lulu, Shi, Ji, Shen, Dachuan, Zhai, Xingyue, Liang, Dapeng, Wang, Jing, Xie, Chunrui, Xia, Zhiyu, Cui, Jing, Liu, Feng, Du, Sha, Meng, Songshu, Piao, Haozhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480197/
https://www.ncbi.nlm.nih.gov/pubmed/37669963
http://dx.doi.org/10.1038/s41420-023-01632-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480197/
https://www.ncbi.nlm.nih.gov/pubmed/37669963
http://dx.doi.org/10.1038/s41420-023-01632-6

Ejemplares similares